SecBot SecBot
8-K ·Filed Aug 10, 2026

SION

Sionna Therapeutics, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed3mo ago SEC0001193125-26-341230
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

The failure of SION-719 in a small but pivotal Phase 2a proof-of-concept trial removes the company's most advanced and visible asset, likely triggering a significant stock decline. The Phase 1 dual-combination data (SION-451+SION-2222) provide an alternative path but remain early-stage, and the capital-preservation language signals potential restructuring or strategic review. Traders should expect high volatility and watch the 8:00 a.m. ET conference call for details on confounders and next steps; near-term downside risk is substantial.

DirectionBearish
Confidencehigh
Horizonimmediate

Drugs in focus

SION drug pipeline →

SION-2222

● Neutral Named in this 8-K
Impact
Phase
Phase 2a (scheduled to initiate Q1 2027); Phase 1 completed
Time to market
At least 3 to 5 years away. The dual combination enters Phase 2a in Q1 2027; a successful Phase 2a and subsequent Phase 3 program plus FDA review would be needed before any approval.
Next catalyst
None dated

What to watchThe next catalyst is the initiation of the AscenSION CF Phase 2a proof-of-concept trial for the SION-451 + SION-2222 dual combination, expected in Q1 2027. If the trial starts on schedule, it signals the company is executing on its restructuring plan; a delay would raise concerns given the company's single-asset focus. The actual Phase 2a topline readout is likely 12+ months after initiation and represents the true binary event for the stock.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.50
T+0 close · Aug 10, 2026 · via day close
Latest settled
−18.89%
T+60 · $3.65
Vs SPY
−16.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $4.50entry
  2. T+1 · 3mo ago +13.33%α +13.65% · $5.10
  3. T+5 · 3mo ago +31.33%α +31.38% · $5.91
  4. T+20 · 2mo ago +62.22%α +63.14% · $7.30
  5. T+60 · 14d ago −18.89%α −16.47% · $3.65
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sionna Therapeutics announced that its Phase 2a PreciSION CF trial of SION-719 failed to meet its key activity endpoint (sweat chloride reduction, p=0.7), and the company is not advancing SION-719 as an add-on to standard of care. The Phase 1 dual-combination trial achieved PK/safety objectives and identified SION-451+SION-2222 as the preferred combination, but next steps are being evaluated as the company plans to preserve capital. This is a material pipeline setback for a clinical-stage biopharma with a $2.3B market cap, significantly de-risking its lead program.

Key Facts

  • Phase 2a PreciSION CF trial of SION-719 did not meet its key activity endpoint: -1.0 mmol/L mean placebo-adjusted sweat chloride change (p=0.7)
  • Company is not advancing SION-719 as an add-on to standard of care
  • Phase 1 trial of SION-451 dual combinations met safety, tolerability, and PK objectives; SION-451 + SION-2222 identified as preferred dual combination
  • Company ended Q2 2026 with approximately $268.3 million in cash and intends to take actions to preserve capital while evaluating next steps for the SION-451 program
  • Trial enrolled 15 adult CF participants homozygous for F508del on stable Trikafta
  • Potential confounders observed: higher-than-expected variability in individual sweat chloride levels and differences in Trikafta exposure between arms

Financial Impact

Lead pipeline candidate SION-719 discontinued as add-on to standard of care; future development spending likely to be curtailed; $268.3M cash cushion provides runway for strategic evaluation

cashpipeline valueR&D spend

Risk Factors

  • Complete value erosion of the SION-719 program, the company's lead candidate
  • Potential delisting or strategic alternatives (sale, partner, pipeline refocus) given capital preservation language
  • Phase 1 dual-combination data are still early and may face similar translational challenges
  • Risk of insufficient data to justify continued standalone investment at current market cap

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-341230
Document: d135438dex991.htm0001193125-26-341230
Document: 0001193125-26-341230-index-headers.html0001193125-26-341230
Document: 0001193125-26-341230-index.html0001193125-26-341230
Document: 0001193125-26-341230.txt0001193125-26-341230

Track record

22 reports on SION

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
  2. Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
  3. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
  5. Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
  6. Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
  7. Aug 10, 202614w ago 8-K Bearish 7/10 Viewing Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
  8. Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
  9. Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
  10. Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 8h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026